Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2002

View Archived Issues

Daiichi decides not to seek marketing approval for nefiracetam in Japan

Development of memantine in Japan extended to mild to moderate AD under new agreement

Corus receives orphan drug designation for inhaled antibiotic in CF patients

HIV entry inhibitor effective as salvage therapy in patients failing conventional treatment

Potential utility of Antrin photoangioplasty further supported by data presented during ACC meeting

Efficacy of etoricoxib significantly superior to placebo in the treatment of chronic low back pain

Prague presentations describe good anti-HBV activity and favorable pharmacokinetics of MIV-210

TAS-108, a safer antiestrogen for breast cancer

Xenova offers a profile of its achievements in 2001

Oral entecavir highly effective in transgenic mouse model of HBV infection

First oral drug developed to treat smallpox infection

Schering-Plough searches for new antibiotics using genomic-derived targets

Cell Genesys discontinues p27/p16 gene therapy collaboration

Monoclonal antibodies for treating autoimmune conditions claimed by Immunex

Schering AG to acquire Collateral Therapeutics

Scientists at Takeda present new factor Xa inhibitors

Novel GnRH antagonists for sex hormone-dependent conditions identified at GSK

Selective COX-2 inhibitors reported in a recent patent from Roche

New antiviral compounds disclosed by Bayer

GlaxoSmithKline presents new compounds for inflammatory and allergic conditions

Daclizumab fails to meet endpoint as maintenance treatment in psoriasis

Nicotinic cholinergic receptors from Targacept have potential for a wide variety of CNS disorders

Research at Corixa leads to new hepatitis B and influenza vaccines

CPMP recommends approval of Tamiflu for influenza in E.U.

FDA approval for Avinza for once-daily treatment of chronic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...